Macrocure nets $49.8mm through IPO
Israeli wound therapy developer Macrocure Ltd. completed its initial public offering in the US, netting $49.8mm through the sale of 5.35mm ordinary shares at $10 (below its intended range of $13-15).
- Medical Devices
- Gene Therapy, Cell Therapy
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com